| Bryan G Barnosky, DO | |
|
50505 Schoenherr Rd, Suite 290, Shelby Township, MI 48315-3140 | |
| (586) 314-0080 | |
| (586) 731-6257 |
| Full Name | Bryan G Barnosky |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 23 Years |
| Location | 50505 Schoenherr Rd, Shelby Township, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073726329 | NPI | - | NPPES |
| 5212785 | Medicaid | MI | |
| 0E00425 | Other | MI | BCBSM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | 5101015127 (Michigan) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 5101015127 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mclaren Macomb | Mount clemens, MI | Hospital |
| Henry Ford Macomb Hospital | Clinton township, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pulmonary And Critical Care Associates Pc | 0547250607 | 22 |
News Archive
This data refutes previous evidence which suggested a high incidence of injury to a patient's cardiac nerves, possibly resulting in accelerated heart rates following the procedure.
Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research to be held April 17-21, 2010 in Washington, D.C.
An accurate assessment of a patient's kidney function is critical for determining eligibility for anticancer treatments.
AstraZeneca today announced new analyses of exenatide once weekly (ExQW) demonstrating a favorable gastrointestinal (GI) tolerability profile, including less frequent upper and lower GI adverse events (AE), compared to shorter-acting glucagon-like peptide-1 receptor agonists (GLP-1RA), exenatide twice daily (ExBID) and liraglutide once daily (LiraQD).
› Verified 5 days ago
| Entity Name | Pulmonary & Critical Care Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598700932 PECOS PAC ID: 0547250607 Enrollment ID: O20040512001399 |
News Archive
This data refutes previous evidence which suggested a high incidence of injury to a patient's cardiac nerves, possibly resulting in accelerated heart rates following the procedure.
Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research to be held April 17-21, 2010 in Washington, D.C.
An accurate assessment of a patient's kidney function is critical for determining eligibility for anticancer treatments.
AstraZeneca today announced new analyses of exenatide once weekly (ExQW) demonstrating a favorable gastrointestinal (GI) tolerability profile, including less frequent upper and lower GI adverse events (AE), compared to shorter-acting glucagon-like peptide-1 receptor agonists (GLP-1RA), exenatide twice daily (ExBID) and liraglutide once daily (LiraQD).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bryan G Barnosky, DO 50505 Schoenherr Rd, Suite 290, Shelby Township, MI 48315-3140 Ph: (586) 314-0080 | Bryan G Barnosky, DO 50505 Schoenherr Rd, Suite 290, Shelby Township, MI 48315-3140 Ph: (586) 314-0080 |
News Archive
This data refutes previous evidence which suggested a high incidence of injury to a patient's cardiac nerves, possibly resulting in accelerated heart rates following the procedure.
Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research to be held April 17-21, 2010 in Washington, D.C.
An accurate assessment of a patient's kidney function is critical for determining eligibility for anticancer treatments.
AstraZeneca today announced new analyses of exenatide once weekly (ExQW) demonstrating a favorable gastrointestinal (GI) tolerability profile, including less frequent upper and lower GI adverse events (AE), compared to shorter-acting glucagon-like peptide-1 receptor agonists (GLP-1RA), exenatide twice daily (ExBID) and liraglutide once daily (LiraQD).
› Verified 5 days ago
Dr. Julia Tesch, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 50505 Schoenherr Rd, Suite 340, Shelby Township, MI 48315 Phone: 586-731-8400 Fax: 526-731-8406 | |
Sima Salahie, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 50505 Schoenherr Rd Ste 340, Shelby Township, MI 48315 Phone: 586-731-8400 Fax: 586-731-8406 | |
Luay Sayed, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 49050 Schoenherr Rd Ste 100, Shelby Township, MI 48315 Phone: 586-566-7870 Fax: 586-566-7850 | |
Paul K Fozo, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 50505 Schoenherr Rd, Suite 340, Shelby Township, MI 48315 Phone: 586-731-8400 Fax: 586-731-8406 | |
Saurabh Gandhi, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 45640 Schoenherr Rd, Suite B, Shelby Township, MI 48315 Phone: 586-247-4300 Fax: 586-532-6496 | |
Dr. Steven M Taormina, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 50505 Schoenherr Rd, Suite 300, Shelby Township, MI 48315 Phone: 586-726-5566 Fax: 586-726-8085 |